Beta

Lexeo therapeutics, inc. common stockLXEO.US Overview

US StockHealthcare
(No presentation for LXEO)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

LXEO AI Insights

LXEO Overall Performance

LXEO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LXEO Recent Performance

3.29%

Lexeo therapeutics, inc. common stock

-1.10%

Avg of Sector

-0.49%

S&P500

LXEO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check LXEO's Trend

LXEO Key Information

LXEO Valuation Metrics

LXEO Profile

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Price of LXEO

LXEO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LXEO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
478.26
PB Ratio
1.76
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
25.99%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
478.26
PB Ratio
1.76
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
25.99%

  • When is LXEO's latest earnings report released?

    The most recent financial report for Lexeo therapeutics, inc. common stock (LXEO) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LXEO's short-term business performance and financial health. For the latest updates on LXEO's earnings releases, visit this page regularly.

  • How much debt does LXEO have?

    As of the end of the reporting period, Lexeo therapeutics, inc. common stock (LXEO) had total debt of 7.89M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does LXEO have?

    At the end of the period, Lexeo therapeutics, inc. common stock (LXEO) held Total Cash and Cash Equivalents of 66.25M, accounting for 0.25 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is LXEO's EPS continuing to grow?

    According to the past four quarterly reports, Lexeo therapeutics, inc. common stock (LXEO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.14. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LXEO?

    Lexeo therapeutics, inc. common stock (LXEO)'s Free Cash Flow (FCF) for the period is -20.08M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 29.11% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of LXEO?

    The latest valuation data shows Lexeo therapeutics, inc. common stock (LXEO) has a Price-To-Earnings (PE) ratio of -3.91 and a Price/Earnings-To-Growth (PEG) ratio of 0.54. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.